ClinicalTrials.gg
RecruitingNCT06617325PHOENYCS FLYUpdated Nov 2, 2026

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

A Phase 3 interventional study of DZP and Placebo in Systemic Lupus Erythematosus, sponsored by UCB Biopharma SRL. Recruiting at 245 sites in 23 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Updated Nov 2, 2026Site recruiting status changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..

Planned enrollment
6th of 21
450 · median 54
Started
2024
the only one that year
Phase 3
9 of 21
2 open now
Registered
19th of 21
by date

Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 6th largest by planned enrollment, is the only one that started in 2024, is one of 9 in phase 3, and was the 19th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lupus Erythematosus, Systemic by UCB S.A., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic lupus erythematosus
  • Dapirolizumab pegol
  • SLE
  • DZP
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be ≥16 years of age, (≥18 years of age for China), unless restricted by local regulation, at the time of signing the form (ICF)
  • Study participants who have moderate to severe disease activity due to either persisting active systemic lupus erythematosus (SLE) or due to an acute worsening of SLE in the scope of frequent relapsing-remitting SLE despite stable standard of care(SOC) medication defined as:

    a. Diagnosed with SLE at least 24 weeks before the Screening Visit by a qualified physician b. Classified by 2019 SLE European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE c. With serological evidence for SLE at Screening as demonstrated by at least 1 of the following: i) Evidence for anti-dsDNA (defined as evidence for anti-dsDNA antibodies in central laboratory) ii) Either complement C3 \<lower limit of normal (LLN) OR complement C4 \<LLN as measured by central laboratory iii) Antinuclear antibodies with a titer of at least 1:80 confirmed by central laboratory in combination with evidence of at least 1 of the following SLE typical autoantibodies:

    1. Anti-Smith (anti-Sm) antibodies (central laboratory or source verifiable history)
    2. Anti-Sjögren's syndrome antibody A (Anti-SSA) (Ro)/Anti-Sjögren's syndrome antibody B (anti-SSB) (La) autoantibodies (central laboratory)
    3. Historical evidence for anti-dsDNA antibodies
    4. Anti-ribonucleoprotein (RNP) autoantibodies (central laboratory) d. Moderately to severely active defined as:

      • British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade B in ≥2 organ systems and/or a BILAG 2004 Grade A in ≥1 organ systems at Screening and Baseline Visit AND
      • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≥6 at the Screening Visit AND
      • SLEDAI-2K without labs ≥4 at Baseline Visit e. Receiving the following standard of care (SOC) medications at stable dose:
      • Antimalarial treatment in combination with and/or or as stand-alone treatment if justified OR
      • Treatment with glucocorticoids and/or immunosuppressants if antimalarial treatment is not appropriate (ie, there is documented intolerance in medical history, documented lack of efficacy, , or lack of availability)

Exclusion criteria

Exclusion Criteria:

  • Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric SLE) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition
  • Study participant has a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies. This includes systemic reactions due to latex allergy
  • Study participant has a history of , except the following treated cancers: cervical carcinoma in situ (after complete resection [eg, curettage, electrodesiccation] not later than 4 weeks prior to the Screening Visit [V1]), basal cell carcinoma, or dermatological squamous cell carcinoma
  • Study participant has a mixed connective tissue disease, scleroderma, and/or overlap syndrome of these diseases with SLE
  • Study participant has evidence of (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or during the study
  • Study participant has active or latent infection
  • Study participant had a reactivated latent infection (eg, cytomegalovirus, herpes simplex virus, or herpes zoster infection) or opportunistic infection (including but not limited to, pneumocystis, cytomegalovirus, or severe herpes zoster infection) within 12 weeks prior to the first study medication infusion (Visit 2) or is currently receiving suppressive therapy for an opportunistic infection
  • Study participants who have received live/ within 6 weeks prior to the first study medication infusion
  • Study participant has used the prohibited medications within the time frame () listed in the Protocol
  • Study participant has previously been randomized within this study or has previously been assigned to treatment with dapirolizumab pegol (DZP) in a study evaluating DZP
  • Study participant has participated in another study of an medicinal product (IMP) within the previous 12 weeks or 5 half-lives of the IMP whatever is longer, or is currently participating in another study of an IMP
  • Study participant has chronic kidney failure stage 4, manifested by estimated (eGFR) \<30 mL/min/1.73m2, or serum creatinine >2.5 mg/dL, or participant has proteinuria >3g/day, or protein:creatinine ratio >340 mg/mmol at the Screening Visit
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Dapirolizumab pegol

    Study participants will receive dapriolizumab pegol throughout the Treatment Period.

    Drug: DZP

  • Placebo comparator
    Placebo

    Study participants will receive placebo throughout the Treatment Period.

    Other: Placebo

Interventions

  • DrugDZP

    Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.

    Also known as: CDP7657

  • OtherPlacebo

    Study participants will receive placebo at prespecified time-points.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48

    A study participant is a BICLA responder if all of the following is fulfilled: a. BILAG 2004 improvement without worsening, defined as BILAG 2004 Grade As at Baseline improved to B/C/D, BILAG 2004 Grade Bs at Baseline improved to C/D, and no BILAG 2004 worsening in other BILAG 2004 organ systems (that had BILAG 2004 Grade C/D/E at Baseline) such that there are no new BILAG 2004 Grades A nor greater than 1 new BILAG 2004 Grade(s) B; and b. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI- 2K) total score compared to Baseline (defined as no increase in SLEDAI-2K total score); and c. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline defined as ≤10 mm increase on a 100 mm visual analog scale Escape treatment intervention as indicated by investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.

    Time frame: Week 48

Secondary outcomes

  1. Achievement of SRI 4 response at Week 48

    The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met): * Reduction in SLEDAI-2K score of ≥4 * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline * No worsening in the PGA compared to Baseline score; "no worsening" is defined as either no worsening or worsening \<10% of the full 100 mm visual analog scale (VAS).

    Time frame: Week 48

  2. Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48

    Severe BILAG flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.

    Time frame: Week 48

  3. Achievement of LLDAS at Week 40 and maintaining LLDAS at Weeks 44 and 48

    Low lupus disease activity state (LLDAS) is defined as: * No significant disease activity as per Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit * Physician's Global Assessment of Disease (PGA) ≤33 mm * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol

    Time frame: Week 40 to Week 48

  4. Change from Baseline to Week 48 in the FATIGUE-PRO Total score

    The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE. It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31). The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time.

    Time frame: From Baseline to Week 48

  5. Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at Baseline to ≤7.5mg/day at Week 36 and maintained through Week 48

    The achievement of a reduction in glucocorticoid dose from \>7.5mg/day prednisone equivalent dose at Baseline to ≤7.5mg/day prednisone equivalent at Week 36 and maintained through Week 48 will be assessed.

    Time frame: From Baseline to Week 48

  6. Achievement of BILAG 2004 improvement without worsening at Week 48

    BILAG 2004 improvement without worsening can be defined as A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.

    Time frame: Week 48

  7. Change from Baseline in PGA at Week 48

    Physician's Global Assessment of Disease (PGA), the investigator will rate the overall status of the study participant. The PGA of disease activity used will be a 100 mm linear scale without anchors. The very far left end is 'very good, asymptomatic and no limitation of normal activities'; the very far right end indicates 'severe disease'.

    Time frame: From Baseline to Week 48

  8. Achievement of prevention of moderate/severe BILAG flares (moderate/severe BILAG flare-free) through Week 48

    A BILAG severe flare is defined as a BILAG 2004 Grade A in any system due to individual items that are new or worse qualifying for the Grade A. Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index. A BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system. Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG-2004 index.

    Time frame: During Treatment Period up to Week 48

  9. Change from Baseline in SLEDAI-2K at Week 48

    SLEDAI-2K measures disease activity. Disease activity in the 30 days prior to and at the time point of the assessment shall be considered. It is a global index and includes 24 clinical symptoms and laboratory variables that are weighted by the type of manifestation, but not by severity or dynamic of the individual item. The total score falls between 0 and 105, with higher scores representing increased disease activity.

    Time frame: From Baseline to Week 48

  10. Change from Baseline in FACIT-Fatigue score at Week 48

    The FACIT (Functional Assessment of Chronic Illness Therapy)-Fatigue scale is a patient-reported outcome (PRO) measure assessing symptoms and impacts of fatigue originally developed in patients with cancer (Cella et al, 2002). It is composed of 13 items, all scored from 0 (Not at all) to 4 (Very much), and uses a recall period of the past 7 days. The FACIT-Fatigue score ranges from 0 to 52 with 0 being the worst possible score and 52 being the best possible score (lowest level of fatigue). To obtain a score from 0 to 52, all negatively worded questions have to be recoded, so that responses range from worst (0) to the best (4) outcome.

    Time frame: From Baseline to Week 48

  11. Percentage of participants with treatment-emergent adverse events (TEAEs) during the study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.

    Time frame: From Baseline until Safety Follow-Up (up to Week 54)

  12. Percentage of participants with serious treatment-emergent adverse events during the study

    A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: 1. Results in death 2. Is life-threatening 3. Requires inpatient hospitalization or prolongation of existing hospitalization 4. Results in persistent disability/incapacity 5. Is a congenital anomaly/birth defect 6. Is an Important medical event

    Time frame: From Baseline until Safety Follow-Up (up to Week 54)

  13. Percentage of participants with treatment-emergent adverse events of special interest during the study

    An adverse event of special interest is any adverse event (AE) that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound.

    Time frame: From Baseline until Safety Follow-Up (up to Week 54)

  14. Percentage of participants with treatment-emergent adverse events of special monitoring during the study

    An adverse event of special monitoring is a product-specific adverse event (AE), adverse reaction, or safety topic considered as requiring special monitoring by UCB.

    Time frame: From Baseline until Safety Follow-Up (up to Week 54)

07

Study locations

238 of 245 sites recruiting
  • Sl0044 50058
    Avondale, Arizona 85392, United States
    Recruiting
  • Sl0044 50550
    Chandler, Arizona 85225, United States
    Recruiting
  • Sl0044 50713
    Gilbert, Arizona 85297, United States
    Recruiting
  • Sl0044 50662
    Glendale, Arizona 85306, United States
    Recruiting
  • Sl0044 50052
    Phoenix, Arizona 85032, United States
    Recruiting
  • Sl0044 50677
    Scottsdale, Arizona 85258, United States
    Recruiting
  • Sl0044 50670
    Searcy, Arkansas 72143, United States
    Recruiting
  • Sl0044 50737
    Beverly Hills, California 90210, United States
    Recruiting
  • Sl0044 50775
    Beverly Hills, California 90211, United States
    Recruiting
  • Sl0044 50257
    La Jolla, California 92037, United States
    Recruiting
  • Sl0044 50275
    La Palma, California 90623-1730, United States
    Recruiting
  • Sl0044 50755
    Los Alamitos, California 90720, United States
    Recruiting
  • Sl0044 50258
    Los Angeles, California 90022, United States
    Recruiting
  • Sl0044 50725
    Menifee, California 92586, United States
    Recruiting
  • Sl0044 50340
    Orange, California 92868, United States
    Recruiting
  • Sl0044 50316
    San Leandro, California 94578, United States
    Recruiting
  • Sl0044 50719
    Aurora, Colorado 80045, United States
    Recruiting
  • Sl0044 50239
    Brandon, Florida 33511, United States
    Recruiting
  • Sl0044 50630
    Clearwater, Florida 33765, United States
    Recruiting
  • Sl0044 50751
    Coral Gables, Florida 33134, United States
    Recruiting
  • Sl0044 50362
    Gainesville, Florida 32610, United States
    Recruiting
  • Sl0044 50766
    Hollywood, Florida 33024, United States
    Recruiting
  • Sl0044 50763
    Margate, Florida 33063, United States
    Recruiting
  • Sl0044 50747
    Miami, Florida 33126, United States
    Recruiting
  • Sl0044 50735
    Miami, Florida 33155, United States
    Recruiting
  • Sl0044 50681
    Miami, Florida 33172, United States
    Recruiting
  • Sl0044 50324
    Plantation, Florida 33324, United States
    Recruiting
  • Sl0044 50698
    Tampa, Florida 33618, United States
    Recruiting
  • Sl0044 50585
    Winter Park, Florida 32789, United States
    Recruiting
  • Sl0044 50566
    Gainesville, Georgia 30501-2418, United States
    Recruiting
  • Sl0044 50659
    Marietta, Georgia 30060, United States
    Recruiting
  • Sl0044 50699
    Chicago, Illinois 60616, United States
    Recruiting
  • Sl0044 50717
    Willowbrook, Illinois 60527, United States
    Recruiting
  • Sl0044 50748
    New Albany, Indiana 47150, United States
    Recruiting
  • Sl0044 50319
    Iowa City, Iowa 52242., United States
    Recruiting
  • Sl0044 50074
    Kansas City, Kansas 66160, United States
    Recruiting
  • Sl0044 50586
    Louisville, Kentucky 40202-5700, United States
    Recruiting
  • Sl0044 50023
    Baton Rouge, Louisiana 70836, United States
    Recruiting
  • Sl0044 50285
    Lake Charles, Louisiana 70605, United States
    Recruiting
  • Sl0044 50660
    New Orleans, Louisiana 70112, United States
    Recruiting
  • Sl0044 50730
    Rockville, Maryland 20850, United States
    Recruiting
  • Sl0044 50219
    Detroit, Michigan 48201, United States
    Recruiting
  • Sl0044 50682
    Kansas City, Missouri 64151, United States
    Recruiting
  • Sl0044 50010
    Brooklyn, New York 11201, United States
    Recruiting
  • Sl0044 50264
    Manhasset, New York 11030, United States
    Recruiting
  • Sl0044 50077
    New York, New York 10021, United States
    Recruiting
  • Sl0044 50241
    Syracuse, New York 13210, United States
    Recruiting
  • Sl0044 50238
    Charlotte, North Carolina 28211, United States
    Recruiting
  • Sl0044 50262
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Sl0044 50365
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • Sl0044 50001
    Jackson, Tennessee 38305, United States
    Recruiting
  • Sl0044 50693
    Murfreesboro, Tennessee 37128, United States
    Recruiting
  • Sl0044 50738
    Bellaire, Texas 77401, United States
    Recruiting
  • Sl0044 50781
    El Paso, Texas 79902, United States
    Recruiting
  • Sl0044 50673
    Fort Worth, Texas 76109, United States
    Recruiting
  • Sl0044 50562
    Frisco, Texas 75035, United States
    Recruiting
  • Sl0044 50773
    Grapevine, Texas 76051, United States
    Recruiting
  • Sl0044 50688
    Houston, Texas 77054, United States
    Completed

    Not enrolling at this site — choose another above.

  • Sl0044 50696
    Houston, Texas 77090, United States
    Recruiting
  • Sl0044 50723
    Houston, Texas 77090, United States
    Recruiting
  • Sl0044 50718
    Mansfield, Texas 76063, United States
    Recruiting
  • Sl0044 50036
    Mesquite, Texas 75150, United States
    Recruiting
  • Sl0044 50061
    Spokane Valley, Washington 99216, United States
    Recruiting
  • Sl0044 60004
    C.a.b.a, Argentina
    Recruiting
  • Sl0044 60002
    Capital Federal, Argentina
    Recruiting
  • Sl0044 60024
    Córdoba, Argentina
    Recruiting
  • Sl0044 60029
    Mendoza, Argentina
    Recruiting
  • Sl0044 60003
    Quilmes, Argentina
    Recruiting
  • Sl0044 60011
    San Juan, Argentina
    Recruiting
  • Sl0044 60014
    San Miguel de Tucumán, Argentina
    Recruiting
  • Sl0044 40002
    Leuven, Belgium
    Recruiting
  • Sl0044 40060
    Liège, Belgium
    Recruiting
  • Sl0044 50771
    Québec, Canada
    Recruiting
  • Sl0044 50259
    Rimouski, Canada
    Recruiting
  • Sl0044 50045
    Toronto, Canada
    Recruiting
  • Sl0044 60018
    Santiago, Chile
    Recruiting
  • Sl0044 20293
    Baotou, China
    Recruiting
  • Sl0044 20128
    Beijing, China
    Recruiting
  • Sl0044 20157
    Beijing, China
    Recruiting
  • Sl0044 20173
    Beijing, China
    Recruiting
  • Sl0044 20201
    Bengbu, China
    Recruiting
  • Sl0044 20291
    Changchun, China
    Recruiting
  • Sl0044 20342
    Changchun, China
    Recruiting
  • Sl0044 20295
    Changsha, China
    Recruiting
  • Sl0044 20186
    Changzhou, China
    Recruiting
  • Sl0044 20137
    Chengdu, China
    Recruiting
  • Sl0044 20019
    Guangzhou, China
    Recruiting
  • Sl0044 20360
    Guangzhou, China
    Recruiting
  • Sl0044 20290
    Guilin, China
    Recruiting
  • Sl0044 20271
    Haikou, China
    Recruiting
  • Sl0044 20296
    Hangzhou, China
    Recruiting
  • Sl0044 20185
    Jinan, China
    Recruiting
  • Sl0044 20364
    Jiujiang, China
    Recruiting
  • Sl0044 20192
    Nanchang, China
    Recruiting
  • Sl0044 20024
    Nanjing, China
    Recruiting
  • Sl0044 20331
    Nanning, China
    Recruiting
  • Sl0044 20272
    Pingxiang, China
    Recruiting
  • Sl0044 20020
    Shanghai, China
    Recruiting
  • Sl0044 20172
    Shanghai, China
    Recruiting
  • Sl0044 20346
    Shantou, China
    Recruiting

Showing the first 100 of 245 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2028, 42 months after the start.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 27, 2024
StartActual
Nov 21, 2024
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed. 3 sites changed recruiting status (2 now active, not recruiting, 1 now completed)
Show 3 sites
  • Sl0044 50688 · Houston, United StatesRecruiting→Completed
  • Sl0044 40139 · Jena, GermanyRecruiting→Active, not recruiting
  • Sl0044 20171 · Sendai, JapanRecruiting→Active, not recruiting
Show 4 added (2 Italy, 1 United States, 1 Peru)
  • Sl0044 50262 · Oklahoma City, United States
  • Sl0044 40859 · Monza E Brianza, Italy
  • Sl0044 40817 · Udine, Italy
  • Sl0044 60008 · San Juan de Lurigancho, Peru
Show 1 removed
  • Sl0044 60008 · San Juan de Lurigancho, Peru
across 3 updates, Oct 2, 2026 – Nov 2, 2026
Show all 3 updates
  1. Nov 2, 2026
    3 sites added
    Show 3 added (2 Italy, 1 Peru)
    • Sl0044 40859 · Monza E Brianza, Italy
    • Sl0044 40817 · Udine, Italy
    • Sl0044 60008 · San Juan de Lurigancho, Peru
  2. Oct 15, 2026
    2 sites changed recruiting status (2 now active, not recruiting)
    Show 2 sites
    • Sl0044 40139 · Jena, GermanyRecruiting→Active, not recruiting
    • Sl0044 20171 · Sendai, JapanRecruiting→Active, not recruiting
    + 1 other change: verification date
  3. Oct 2, 2026
    1 site added, 1 site removed. Sl0044 50688 is now Completed
    Show site
    • Sl0044 50262 · Oklahoma City, United States
    Show 1 removed
    • Sl0044 60008 · San Juan de Lurigancho, Peru

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06617325
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Nov 21, 2024
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

UCB Cares
Contact
ucbcares@ucb.com
1-844-599-2273
UCB Cares
Contact
001 844 599 2273
UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapirolizumab pegol

Start the discussion